Merck Gets CHMP Backing of Keytruda in Certain Ovarian Cancers
Merck Gets CHMP Backing of Keytruda in Certain Ovarian Cancers is drawing significant interest across the industry.
By Colin Kellaher Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for...
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Half of xAI's Founding Team Has Left the Company
- India and Mauritius Strengthen Ties Ahead of AI-Impact Summit
- Transformative Urban Sanitation: Chennai's Quiet Revolution
- Heathrow chair Jansen takes off with US software firm Xplor
Source: Original →